Introduction
The reciprocal translocation t(12;21)(p13;q22) fuses the helixloop-helix domain of the TEL gene to the DNA binding and trans-activation domains of the AML1 gene. 1, 2 As the translocation is cryptic and usually escapes diagnosis on conventional cytogenetic study, 3, 4 molecular techniques such as RT-PCR have to be employed for its detection. Subsequently, TEL/AML1 gene fusion is found to be the most common gene rearrangement in childhood acute lymphoblastic leukemia (ALL) of B-lineage.
3,5-8 TEL/AML1 gene fusion is not seen in childhood acute myeloid leukemia 9 and is very rare in adult ALL. 10 TEL/AML1 forms dimers both with itself and with wildtype TEL, 6 and may therefore exert a dominant negative effect on TEL. 2 Moreover, fusion with TEL converts AML1 from an activator to a repressor of transcription, thus altering the expression of genes normally regulated by the AML1-CBF␤ complex. 11 This fusion is generally believed to confer a favorable prognosis in childhood ALL. 3, [5] [6] [7] [8] 12 The good prognosis of TEL/AML1 is being challenged by two studies showing similar incidence of TEL/AML1 fusion (20-24%) in relapsed patients, 13, 14 although three recent studies show a figure of Ͻ10%. [15] [16] [17] It is plausible that the relapse-free survival in childhood ALL with TEL/AML1 fusion may be affected by treatment intensity 18, 19 or secondary genetic events, and supports the need for a prospective analysis of prognosis in this cohort of patients.
More recently, the TEL/AML1 gene fusion is shown to have originated in the prenatal period based on detecting the same leukemia clone-specific TEL/AML1 fusion sequence in identical twins 20 and in neonatal blood spots of children with ALL. 21 The low concordance rate of around 5% for leukemia in monozygotic twins 22 suggests that, while TEL/AML1 fusion may initiate disease in utero, it is in most cases insufficient for leukemia. Moreover, in a pair of identical twins with concordant ALL and TEL/AML1 fusion, the latency of disease is variable and may be protracted, reflecting the timing of critical secondary events. 23 Taken together, these observations suggest the need for important secondary and post-natal event or events in the promotion of childhood ALL with TEL/AML1 fusion as the initiating factor. This contention is supported by a recent series showing that 146 out of 169 (86.3%) childhood ALL with TEL/AML1 fusion had chromosomal abnormalities in addition to the cryptic t(12;21), reflecting the need for additional molecular events. 24 A well-documented secondary change is the deletion of the second TEL allele in this group of patients. 7 We investigated a cohort of childhood ALL with TEL/AML1 gene fusion by a combination of molecular cytogenetic techniques in order to detect additional or secondary genetic alterations, which showed that such changes were indeed prevalent in this molecular subtype of childhood ALL.
Materials and methods

Patient material and detection of TEL/AML1 fusion
Sixty-five consecutive cases of all childhood ALL diagnosed in Queen Mary Hospital, Hong Kong, from 1997 to 1999 were collected and RNA of marrow cells was extracted according to standardized protocols. The presence of TEL/AML1 chimeric transcript was detected by RT-PCR using nested primers as previously described. 25 
Conventional cytogenetics and FISH
Conventional cytogenetics was performed on bone marrow cells by synchronized and non-synchronized short-term culture supplemented by direct harvest based on a previously published protocol. 26 FISH was performed on metaphases and/or interphase nuclei prepared from cells in Carnoy's fixative. In two patients with inadequate samples for study (Table 1 , cases 2 and 6), FISH was performed on bone marrow cells on cytospin preparation that were stored at −70°C.
Detection of TEL/AML1 gene fusion was performed by a dual-color locus-specific TEL/AML1 translocation probe (Vysis, Downers Grove, IL, USA), with the TEL probe directly labeled with the SpectrumGreen fluorophore and the AML1 probe directly labeled with SpectrumOrange fluorophore. The TEL probe starts between exons 3 and 5 and extends approximately 350 kb towards the telomere on chromosome 12. The AML1 probe, approximately 500 kb in size, spans the entire gene and therefore gives an extra split signal when TEL/AML1 gene fusion is present, the absence of which helps to prevent co-localization of signals from chromosomes 12 and 21 to be falsely interpreted as TEL/AML1 gene fusion. A minimum of 200 interphase nuclei was analyzed. The false positive and negative rates of the FISH probe were 2% and 0%, respectively. The copy number of chromosome 21 was determined by a chromosome 21 enumeration probe (Vysis) directly labeled with SpectrumOrange fluorophore that contained unique DNA sequences complimentary to the loci D21S259, D21S341 and D21S342 found within the 21q22.13 to 21q22.2 region on the long arm of chromosome 21. The copy number of chromosome 12 was performed by a centromeric probe (Vysis) directly labeled with SpectrumGreen. Whole chromosome painting (WCP) was performed with a digoxigenin-labeled WCP probe for chromosome 12 (Oncor, Gaithersburg, MD, USA) that was detected using a FITC-labeled sheep anti-digoxigenin antibody (Oncor), and also a WCP probe for chromosome 21q directly labeled with SpectrumOrange (Vysis).
CGH
CGH was performed on patients 4 and 5 (Table 1 ) as previously described. 27 Briefly, leukemic DNA and reference norLeukemia mal DNA, each labeled with a different fluorochrome, were allowed to competitively co-hybridize on to normal metaphase chromosomes for 72 h. Ten metaphases were captured and analyzed by the use of a Leica Q550CW Cytogenetics Workstation equipped with the QCGH software (Leica Imaging System, Cambridge, UK), and the average ratio profile was plotted. Thresholds for gain or loss of chromosomal material was defined as a green (tumor) to red (normal) fluorescence ratio of Ͼ1.25 or Ͻ0.75, respectively.
AML1 gene expression
A semi-quantitative RT-PCR experiment was performed that compared the expression of AML1 gene in TEL/AML1-positive ALL with normal control marrow cells. The housekeeping gene GAPDH was used as control for abundance of mRNA. For patients that showed extra copies of AML1 gene, RNA was extracted from the bone marrow specimen at diagnosis. cDNA samples were prepared and the AML1 transcripts were amplified by primers C, 5′-GAGGGAAAAGCTTCACTCTGA-3′, and 2B, 5′-GTTGAGAGTCGACTGGAAAG-3′ as previously described. 28 GAPDH transcript was amplified by primers 5′-CTCAGACACCATGGGG-3′ and 5′-ATGATCTTGAGGCTGT TGTCATA-3′. The amplified bands corresponding to AML1 and GAPDH transcripts were quantified using a gel documentation system (BioRad, Hercules, CA, USA). The fold difference was expressed as the ratio of AML1 to GAPDH transcript in the leukemic sample divided by that observed in a normal sample.
Results
Patient characteristics (Table 1)
Among 65 childhood ALL patients diagnosed in the study period, 12 patients (18.5%) harbored TEL/AML1 fusion transcript as detected by RT-PCR, and samples were subject to further molecular cytogenetics study. They comprise nine males and three females with a median age at presentation of 6 years (range: 2-14 years). Immunophenotyping showed that 11 patients had B-lineage ALL, with aberrant expression of myeloid markers noted in six patients (54.5%). In one patient (case 10), the diagnosis was that of T-lymphoblastic lymphoma/leukemia syndrome, and blast cells were immunoreactive for Tdt, cytoplasmic CD3 and CD99 (O13) but negative for CD1a. Ten patients were studied at presentation and two (cases 3 and 11) at relapse. The median blast percentage in the bone marrow was 89% (range: 73-98%). Unfortunately, cytogenetic data were available in only eight patients (66.7%), and karyotypic abnormalities were detected in three patients (37.5%), including hyperdiploid cells (case 1), trisomy 21 as the sole abnormality (case 2) and complex changes (case 5). None of the patients showed a morphologically detectable t(12;21).
FISH and CGH
TEL/AML1 gene fusion was demonstrated in all 12 cases. The median size of the TEL/AML1 clone was 47.3% of all cells (range: 5.5-97.5%). Normal cells were uniformly present with a median population size of 14.3% (range: 2.5-93.5%). Secondary or additional changes were noted in seven patients (58%).
Case 1:
All cells (8%) with TEL/AML1 fusion showed +21 as an additional abnormality in the form of one extra AML1 signal (Figure 1a) , as confirmed by the chromosome 21 enumeration probe. However, cells with +21 (17.5%) and tetrasomy 21 (57%) without TEL/AML1 fusion were identified (Figure 1b) , which was in keeping with results on conventional cytogenetics. The TEL/AML1 fusion most probably originated from the +21 clone, as was the clone with one additional +21.
Case 2:
TEL/AML1 fusion was detected in 10% of cells (Figure 1c) . The predominant clone (70.5%) harbored +21 without TEL/AML1 fusion (Figure 1d) , which evolved into a clone (6%) with concurrent +21 and +12 as confirmed by enumeration probes for chromosomes 12 and 21 ( Figure 1e ).
Case 3:
The predominant clone showed TEL/AML1 fusion with +21 as a secondary change (90%), which was confirmed by a chromosome 21 enumeration probe. Interestingly, 7.5% of cells showed TEL/AML1 fusion without +21, which suggested, for this particular patient, the latter was an evolutionary change in the TEL/AML1 clone.
Case 4:
Extra copies of the AML1 gene, approximately four to five in number, was arranged in tandem on the long arm of chromosome 21, both in cells with (5.5%, Figure 1f without (88.5%, Figure 1g ) TEL/AML1 gene fusion. The fusion signal was detected in both interphase and metaphase. Marked amplification of chromosome 21q region was also demonstrated on CGH study of bone marrow sample (Figure 1h ).
Case 5:
TEL/AML1 fusion was detected in 96.5% of cells, in which 8.5% showed loss of the wild-type TEL allele, and a chromosome 12 enumeration probe showed only one signal. In the other 88% of cells with TEL/AML1 fusion, one extra AML1 split signal was noted, and was confirmed by WCP probes for chromosomes 12 and 21q to be duplication of der (12)t(12;21)(p13;q22) (Figure 1i) , most probably as an evolutionary event from the clone in which the normal chromosome 12 was deleted. CGH results confirmed loss of chromosome 6q material as shown on conventional cytogenetics (Figure 2a) , loss of chromosome 12pter and gain of 21qter material that arises from duplicated der (12)t(12;21), and showed that additional chromosomal material on 17p to be derived from Xq ( Figure 2b 
Case 6:
TEL/AML1 fusion was detected in 85% of all cells, in which 81.5% showed duplication of gene fusion in the form of two fusion signals (Figure 1j) . A single copy of TEL/AML1 fusion was noted in 3.5% of cells, illustrating that the duplication of TEL/AML1 fusion gene occurred as a secondary event.
Case 7:
Deletion of the normal TEL allele was detected in all cells showing TEL/AML1 gene fusion. These cells harbored two copies of chromosome 12 as determined by an enumeration probe.
AML1 gene expression
Both the normal and leukemic samples showed two transcripts, wild-type and alternative spliced (⌬6) transcripts, that differed by 200 bp in size, corresponding to deletion of exon 6 in the latter transcript ( Figure 3) . Results in two patients (cases 3 and 4) in which adequate samples were available both showed an increase in AML1 gene expression, which paralleled the increase in copy number of the AML1 gene. No RNA sample was available for cases 1 and 2 that also showed extra copies of chromosome 21. Patient 3 showed a 4.5-fold increase in wide-type transcript and a 4.8-fold increase in the alternatively spliced (⌬6) transcript. Patient 4 showed a 5.7-fold increase in the wide-type transcript and a 6.7-fold increase in the alternatively spliced (⌬6) transcript.
Discussion
Current evidence suggests that in childhood ALL with t(12;21), while the disease is most probably initiated by TEL/AML1 fusion, critical secondary events are pivotal for leukemogen- esis. Many secondary genetic aberrations have since been described in association with TEL/AML1 fusion. Deletion of the other TEL allele is most frequently encountered. 7, [29] [30] [31] The wild-type TEL allele may function as a tumor suppressor and may mechanistically be inhibited by the TEL/AML1 fusion product in a dominant negative fashion (reviewed in Ref. 32) . Alternatively, the TEL gene production may trap and thereby inactivate the TEL/AML1 protein, 2 so that the leukemic phenotype requires deletion of the normal TEL allele. In the present series, TEL deletion was detected in patients 5 and 7, with the former patient showing deletion of the normal TEL in the form of loss of normal chromosome 12 ( Table 1 ). The subsequent duplication of der (12)t(12;21) in 88% of cells effectively resulted in deletion of 12p, and this was confirmed by CGH. The low prevalence of TEL deletion in the present series is mainly due to the large size of the TEL probe (350 kb) so that a small deletion may escape detection.
Duplication of the fusion gene is rare, but has been recognized 33 and may be in the form of duplication of der (21)t(12;21) 34 or ider(21)(q10)t(12;21)(p12;q22). 35 The fusion gene is duplicated in one patient in our series (8.3%), the significance of which is presently uncertain. The TEL/AML1 chimeric transcript was detected in all patients with t(12;21), whereas the reciprocal AML1/TEL transcript was only found in a subset of patients. 7 Moreover, the der(21)t(12;21) was consistently formed in childhood ALL with t(12;21) despite changes involving der (12) or the other homologue of chromosome 12. 36 These observations show that TEL/AML1 gene fusion on der(21)t(12;21) plays a critical role in leukemogenesis. The significance of der (12)t(12;21) duplication as seen in patient 5, apart from resulting in 12p deletion, remains to be defined.
Trisomy 21 was shown to be a recurrent secondary abnormality in childhood ALL with TEL/AML1 gene fusion, detected in six out of 41 patients (14.6%) at diagnosis in one study. 34 The association between TEL/AML1 fusion and +21 is also noted in two patients (cases 1 and 3) of our series (16.7%). In patient 3, it is apparent that +21 exists as an evolutionary change. Interestingly, the presence of +21 cells without TEL/AML1 fusion in patient 1 showed that the fusion most probably evolves from a pre-existing +21 clone. This observation may challenge the contention of an alternative pathway for leukemogenesis in constitutional +21, based on the absence of TEL/AML1 fusion in ALL occurring in children with Down's syndrome. 37 Moreover, it is possible that in case 1 two independent leukemic clones exist, one bearing t(12;21) in addition to +21, and the second bearing the classical hyperdiploid karyotype without t(12;21). Hyperdiploidy of 52-58 chromosomes, a good prognostic marker, has previously been shown not to be associated with t(12;21). 24 However, no cells in Carnoy's fixative was available for further FISH experiments with TEL/AML1 translocation probe and chromosomes commonly over-represented in hyperdiploidy. It is also of note that a +21 clone distinct from cells with TEL/AML1 fusion occurs in patient 2. Hence despite the association between TEL/AML1 fusion and +21, the possibility remains that the two aberrations may actually exist in separate clones. Among three cases in which additional changes were detected (patients 1, 2 and 4), cells bearing TEL/AML1 fusion existed as a small clone. The RT-PCR in these cases was repeated to confirm positivity. The percentages of cells with fusion were significantly above the false positive rate of 2% as determined on control samples by the TEL/AML1 translocation probe.
The contribution of +21 to the pathogenesis of childhood ALL with TEL/AML1 fusion remains elusive. Amplification of chromosomal region 21q22 including the AML1 gene has recently been recognized in childhood ALL. 38 In our series of childhood ALL with TEL/AML1 fusion, extra copies of AML1 gene is detectable by FISH in three out of 12 cases (25%). Using a FISH strategy similar to ours, amplification of AML1 in the form of extra gene copies is detected in childhood ALL with 33, 39 and without 33 TEL/AML1 gene fusion. These findings suggest that AML1 amplification is the target event in +21 or the 21q22 amplicon, and may play an important role in leukemogenesis. Patient 4 in our series lends support to this hypothesis, since amplification of 21q22 as detected by CGH is clearly shown by FISH to involve AML1 amplification, which occurs as tandem gene duplication on chromosome 21q. Moreover, this case illustrates that AML1 amplification may occur in the absence of +21. Finally, AML1 gene expression studies using a semi-quantitative method on patients 3 and 4 show enhanced expression level that correlates with an increase in gene copy number. Taken together, our findings suggest that AML1 amplification is an important additional or secondary genetic event in childhood ALL with TEL/AML1 fusion and may be the genetic basis behind +21 and the 21q22 amplicon in such patients. Both TEL and AML1 contribute co-repressor interaction domains to the fusion protein on deletional mutagenesis, 40 and it is plausible that the amplified AML1 has a synergistic role with the fusion protein in repression of transcription.
While TEL/AML1 fusion is believed to be restricted to Blineage ALL, case 10 of the present series showed a T-ALL phenotype. Interestingly, another case of T-ALL has previously been reported 31 to show TEL rearrangement (presumably from TEL/AML1 fusion) and LOH at KIP1 locus downstream to the other TEL allele, but no direct detection of TEL/AML1 fusion was performed in that case.
In conclusion, our findings demonstrate that additional or secondary genetic aberrations including AML1 amplification are frequent in childhood ALL with TEL/AML1 gene fusion. These genetic changes are expected to play critical roles in disease progression.
